NeuBase Therapeutics – Consensus Indicates Potential 92.5% Upside

Broker Ratings

NeuBase Therapeutics with ticker code (NBSE) now have 6 analysts in total covering the stock. The consensus rating is ‘Strong_Buy’. The target price ranges between 18 and 13 and has a mean target at 15.67. Now with the previous closing price of 8.14 this is indicating there is a potential upside of 92.5%. The 50 day MA is 8.06 and the 200 day MA is 8.32. The company has a market capitalisation of $180m. Find out more information at: http://www.neubasetherapeutics.com

The potential market cap would be $347m based on the market concensus.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

NeuBase Therapeutics, a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company’s proprietary peptide-nucleic acid antisense oligonucleotide (PATrOL) platform focuses on addressing Huntington’s disease (HD) and myotonic dystrophy, as well as other genetic disorders. Its lead programs include NT0100, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the HD messenger ribonucleic acid (mRNA); and NT0200, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the myotonic dystrophy type 1 disease mRNA. NeuBase Therapeutics is headquartered in Pittsburgh, Pennsylvania.

Good news travels fast (but only if you make that happen). Share on:

Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on email
Email
Share on reddit
Reddit

AIM All Share Index